Home Cart Sign in  
Chemical Structure| 1380392-05-1 Chemical Structure| 1380392-05-1

Structure of JMS-17-2
CAS No.: 1380392-05-1

Chemical Structure| 1380392-05-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JMS-17-2

CAS No. :1380392-05-1
Formula : C25H26ClN3O
M.W : 419.95
SMILES Code : O=C1C2=CC=CN2C3=C(C=CC=C3)N1CCCN4CCC(C5=CC=C(Cl)C=C5)CC4
MDL No. :MFCD30489012
InChI Key :WOSMCMULWWHMIV-UHFFFAOYSA-N
Pubchem ID :57382073

Safety of JMS-17-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of JMS-17-2

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
glutamatergic neurons in ACC brain slices 10 nM 30 min To investigate the effect of JMS-17-2 on the excitability of glutamatergic neurons, results showed that JMS-17-2 treatment decreased the frequency of action potentials and increased the rheobase. PMC10031886
SKBR3 human breast cancer cells 10nM 30 min To evaluate the effect of JMS-17-2 on CX3CR1 signaling pathway, results showed that JMS-17-2 inhibited FKN-induced ERK phosphorylation. PMC5070649
MDA-231 human breast cancer cells 1nM, 10nM, 100nM 6 h To evaluate the effect of JMS-17-2 on MDA-231 cell migration, results showed that JMS-17-2 significantly reduced the migration of breast cancer cells. PMC5070649

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Prostate cancer xenograft model Intraperitoneal injection 2.5 mg/kg Once daily JMS-17-2 prominently sensitized these PDXs to capivasertib PMC11245161
Rats Acute Intermittent Hypoxia Model Intrathecal injection 10 mM Single dose, experiments conducted 30 minutes post-administration JMS-17-2 significantly attenuated severe acute intermittent hypoxia-induced phrenic long-term facilitation (pLTF) by inhibiting CX3CR1 receptors, indicating the critical role of CX3CR1 in severe hypoxia-induced pLTF. PMC11605081
mice nicotine-induced chronic pain model intra-ACC injection 0.5 ng/nL single injection To investigate the effect of JMS-17-2 on nicotine-induced chronic pain, results showed that JMS-17-2 alleviated nicotine-induced chronic allodynia. PMC10031886
SCID mice Breast cancer metastasis model Intraperitoneal injection 10mg/Kg Twice daily for three weeks To evaluate the effect of JMS-17-2 on breast cancer metastasis, results showed that JMS-17-2 significantly reduced tumor metastasis and growth. PMC5070649

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.91mL

2.38mL

1.19mL

23.81mL

4.76mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories